Notably, the phase I trial CheckMate 012 found that advanced NSCLC patients could benefit from nivolumab regardless of PD-L1 expression using 1% and 5% as cutoff values, whereas nivolumab was associated with higher objective response rate (ORR) at the prespecified PD-L1 expression levels of 10% or higher, 25% or higher, and 50% or higher [10]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.